Fractyl Health, Inc.
fractyl.comWhat Do They Do?
Develops an endoscopic treatment candidate and pancreatic gene therapies for people with obesity and diabetes.
10-K for FY2025, filed Mar 24, 2026We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”).…View ↗
The Revita DMR System (“Revita”), our lead product candidate, is based on our insights surrounding the potential role of the gut in…View ↗
We are also developing Rejuva, our novel and locally administered, adeno-associated virus (“AAV”)-delivered pancreatic gene therapy…View ↗
Who Are Their Customers?
Targets people with obesity seeking to maintain weight loss after drug treatment and people with diabetes. If Revita is approved, Fractyl plans to work with gastrointestinal endoscopists through a center-of-excellence model and a potential physician-driven platform partner.
10-K for FY2025, filed Mar 24, 2026The Revita DMR System (“Revita”), our lead product candidate, is based on our insights surrounding the potential role of the gut in…View ↗
Our lead candidate from the Rejuva platform, RJVA-001, is designed to be delivered to the pancreas via a single endoscopic intervention to…View ↗
If Revita is approved in the U.S. for a weight maintenance indication, we plan to execute an efficient “hub-and spoke” commercialization…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$25.5MView ↗
- ▼ −8% (Loss)
- vs −$27.9M in Q2 FY2025
-
Sep 10, 2026
Nasdaq notified Fractyl that its shares are subject to delisting
The company intends to request a hearing, which would stay any suspension or delisting while the process concludes.
Sources
8-K, filed Sep 11, 2026
As previously disclosed, on March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications…View ↗
Loading...
